Arcus Biosciences, Inc.

William Marsh Rice University

Bristol-myers Squibb Compnay

The Scripps Research Institute

Other

Studiengesellschaft Kohle Mbh

Harvard College

Debashis Mandal

Jay Patrick Powers

Manmohan Reddy Leleti

Brandon Reid Rosen

Joel Worley Beatty

Jenna Leigh Jeffrey

Erick Allen Lindsey

Anh Thu Tran

Steven Donald Jacob

Kyriacos Costa Nicolaou

Jaroslaw Kalisiak

Xuelei Yan

Kenneth Victor Lawson

Dillon Harding Miles

Rhiannon Thomas-Tran

Yongli Su

Samuel Lawrie Drew

Tezcan Guney

Sanjeev Gangwar

Yam B Poudel

Naidu S Chowdari

Ehesan Ul Sharif

Guillaume Mata

Balint Gal

Artur Karenovich Mailyan

Clayton Hardman

Zhang Wang

Kai Yu

Matthew Epplin

Hyunyoung Moon

Jeremy Thomas Andre Fournier

Karl T Haelsig

Laurent Debien

Min Lu

Rebecca Louise Grange

Dionisios Vourloumis

Tobias Ritter

Eric Newcomb

Laurent Pierre Paul Debien

Constanze Neumann

Martin Georg Strebl-Bantillo

Ehesan Ui Sharif

Corinne Nicole Foley

Jeremy Fournier

Rohan Diliprao Erande

Mohammad Hassan Beyzavi

Jun Yin

Phillipp Klahn

Ehesan U I Sharif

Eric Thomas Newcomb

Philipp Klahn

Dionosios Vourloumis

Rohan Erande

Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.

Inhibitors of ARG1 and/or ARG2

Compound that is an inhibitor of at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Azolopyrimidine for the treatment of cancer-related disorders

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

Compound that inhibit at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Pyridone A2R antagonists

Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

CD73 inhibitors

Compounds that inhibit HIF-2&#x3b1;, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2&#x3b1;.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2&#x3b1;

The present invention refers to a process for transition-metal-assistedF-deoxyfluorination of phenols. The transformation benefits from readily available phenols as starting materials, tolerance of moisture and ambient atmosphere, large substrate scope, and translatability to generate doses appropriate for positron emission tomography (PET) imaging.

Process for deoxyfluorination of phenols

In one aspect, the present disclosure provides new analogs of uncialamycin. The present disclosure also provides novel synthetic pathways to obtaining uncialamycin and analogs thereof. Additionally, the present disclosure also describes methods of use of uncialamycin and analogs thereof. In another aspect, the present disclosure provides antibody-drug conjugates which may be used to treat cancer or another disease or disorder.

Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents

In one aspect, the present disclosure provides tubulysin analogs of the formula (I) wherein R, R, R, R, X, X, X, and Aare as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. 

Desacetoxytubulysin H and analogs thereof

In one aspect, the present disclosure provides new analogs of uncialamycin of formulae (I) and (II). The present disclosure also provides novel synthetic pathways to obtaining uncialamycin and analogs thereof. Additionally, the present disclosure also describes methods of use of uncialamycin and analogs thereof. In another aspect, the present disclosure provides antibody-drug conjugates comprising the compounds of formulae (I) and (II). 

Growing community of inventors

Fremont, CA, United States of America

Debashis Mandal